April 14, 2014
To support work being done to find treatments and a cure, we have awarded 15 research grants to PKD researchers. We will spend nearly $2.4 million over the next two years on these grants. The awardees represent top researchers and physician scientists throughout the United States, as well as Canada and Italy.
Five of the research grants focus on the development of a treatment for PKD so our patients have something that will slow the progression of the disease. The remaining ten are discovery research, which focuses on understanding the way in which cysts develop or enlarge in PKD. This must be conducted in order to identify cell compounds and pathways before therapy development can be done.
March 24, 2014
(Tokyo, Japan) - Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca® (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD.
In Europe, as of December, 2013, an application for regulatory approval of tolvaptan in ADPKD had been received and is under review. In the United States, based on a review issued by the FDA, Otsuka is having continued discussions regarding supplementary data and the path forward for resubmission.
Read the full news release from Otsuka
Voices of PKD
The spring, for many, signals a new start and a perfect time to set new goals for the rest of the year. For 21-year-old Brianna Rodgers of Grapevine, Texas, 2014 is her year to make a difference in the PKD community. "I just want to take the opportunity to do something good," she said.
Flash back one decade – Rodgers was diagnosed with polycystic kidney disease (PKD) at just 11 years old, making her the youngest person in a family full of PKD patients to deal with the disease.